Apolipoprotein E knockout as the basis for mouse models of dyslipidemia-induced neuropathy

Experimental Neurology

Volumn 239, Issue 1, 2013, Pages 102-110

  Hinder, Lucy M ^a   Vincent, Andrea M ^a   Hayes, John M ^a   McLean, Lisa L ^a   Feldman, Eva L ^a  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Apolipoprotein B48; Apolipoprotein E; Diabetes; Dyslipidemia; Lipid profile; Mouse; Peripheral neuropathy

Indexed keywords

APOLIPOPROTEIN B48; APOLIPOPROTEIN E; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETIC NEUROPATHY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE MODEL; DYSLIPIDEMIA; GENE INACTIVATION; GENETIC MANIPULATION; GENOTYPE; HYPERGLYCEMIA; HYPERLIPIDEMIA; LIPID METABOLISM; MALE; MOUSE; MOUSE STRAIN; NERVE FUNCTION; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; APOLIPOPROTEINS E; BEHAVIOR, ANIMAL; BLOOD GLUCOSE; BODY WEIGHT; CHOLESTEROL; DATA INTERPRETATION, STATISTICAL; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; ELECTROPHYSIOLOGICAL PHENOMENA; LEPTIN; LIPIDS; LIPOPROTEINS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PAIN MEASUREMENT; PERIPHERAL NERVOUS SYSTEM DISEASES; TRIGLYCERIDES;

EID: 84868248256     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2012.10.002     Document Type: Article

References (35)

1. Ansquer J.C., Foucher C., Aubonnet P., Le Malicot K. Fibrates and microvascular complications in diabetes-insight from the FIELD study. Curr. Pharm. Des. 2009, 15:537-552.
2. Barile G.R., Pachydaki S.I., Tari S.R., Lee S.E., Donmoyer C.M., Ma W., Rong L.L., Buciarelli L.G., Wendt T., Horig H., Hudson B.I., Qu W., Weinberg A.D., Yan S.F., Schmidt A.M. The RAGE axis in early diabetic retinopathy. Invest. Ophthalmol. Vis. Sci. 2005, 46:2916-2924.
3. Boyles J.K., Pitas R.E., Wilson E., Mahley R.W., Taylor J.M. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J. Clin. Invest. 1985, 76:1501-1513.
4. Buzello M., Tornig J., Faulhaber J., Ehmke H., Ritz E., Amann K. The apolipoprotein e knockout mouse: a model documenting accelerated atherogenesis in uremia. J. Am. Soc. Nephrol. 2003, 14:311-316.
5. Cheng H.T., Dauch J.R., Hayes J.M., Yanik B.M., Feldman E.L. Nerve growth factor/p38 signaling increases intraepidermal nerve fiber densities in painful neuropathy of type 2 diabetes. Neurobiol. Dis. 2012, 45:280-287.
6. Clemens A., Siegel E., Gallwitz B. Global risk management in type 2 diabetes: blood glucose, blood pressure, and lipids-update on the background of the current guidelines. Exp. Clin. Endocrinol. Diabetes 2004, 112:493-503.
7. Donahue J.E., Johanson C.E. Apolipoprotein E, amyloid-beta, and blood-brain barrier permeability in Alzheimer disease. J. Neuropathol. Exp. Neurol. 2008, 67:261-270.
8. Drory V.E., Groozman G.B., Rubinstein A., Korczyn A.D. Hypertriglyceridemia may cause a subclinical peripheral neuropathy. Electromyogr. Clin. Neurophysiol. 1999, 39:39-41.
9. Fullerton S.M., Strittmatter W.J., Matthew W.D. Peripheral sensory nerve defects in apolipoprotein E knockout mice. Exp. Neurol. 1998, 153:156-163.
10. Gonen B., Patsch W., Kuisk I., Goldberg A., Phair R., Schonfeld G. Altered HDL subclasses in endogenous hypertriglyceridemia are not affected by weight reduction. Metabolism 1985, 34:494-501.
11. Gotoda T., Shirai K., Ohta T., Kobayashi J., Yokoyama S., Oikawa S., Bujo H., Ishibashi S., Arai H., Yamashita S., Harada-Shiba M., Eto M., Hayashi T., Sone H., Suzuki H., Yamada N. Diagnosis and management of type I and type V hyperlipoproteinemia. J. Atheroscler. Thromb. 2012, 19:1-12.
12. Inaba H., Kato K., Yano T. Effect of trapidil on neuropathy in diabetic mice. Nihon Yakurigaku Zasshi 1986, 88:95-99.
13. Isomaa B., Henricsson M., Almgren P., Tuomi T., Taskinen M.R., Groop L. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001, 44:1148-1154.
14. Kassem H.S., Azar S.T., Zantout M.S., Sawaya R.A. Hypertriglyceridemia and peripheral neuropathy in neurologically asymptomatic patients. Neuro Endocrinol. Lett. 2005, 26:775-779.
15. Kern T.S., Berkowitz B.A., Feldman E.L. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) meeting summary: advances toward measuring diabetic retinopathy and neuropathy: from the bench to the clinic and back again (April 4-5, 2007, Baltimore, Maryland). J. Diabetes Complications 2009, 23:219-223.
16. Kinosian B., Glick H., Garland G. Cholesterol and coronary heart disease: predicting risks by levels and ratios. Ann. Intern. Med. 1994, 121:641-647.
17. Lane R.M., Farlow M.R. Lipid homeostasis and apolipoprotein E in the development and progression of Alzheimer's disease. J. Lipid Res. 2005, 46:949-968.
18. Lee J.H., Cox D.J., Mook D.G., McCarty R.C. Effect of hyperglycemia on pain threshold in alloxan-diabetic rats. Pain 1990, 40:105-107.
19. Lloyd D.J., McCormick J., Helmering J., Kim K.W., Wang M., Fordstrom P., Kaufman S.A., Lindberg R.A., Veniant M.M. Generation and characterization of two novel mouse models exhibiting the phenotypes of the metabolic syndrome: Apob48-/-Lepob/ob mice devoid of ApoE or Ldlr. Am. J. Physiol. Endocrinol. Metab. 2008, 294:E496-E505.
20. Mahley R.W. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988, 240:622-630.
21. Massaro D., Massaro G.D. Apoetm1Unc mice have impaired alveologenesis, low lung function, and rapid loss of lung function. Am. J. Physiol. Lung Cell. Mol. Physiol. 2008, 294:L991-L997.
22. McManis P.G., Windebank A.J., Kiziltan M. Neuropathy associated with hyperlipidemia. Neurology 1994, 44:2185-2186.
23. McMillen T.S., Heinecke J.W., LeBoeuf R.C. Expression of human myeloperoxidase by macrophages promotes atherosclerosis in mice. Circulation 2005, 111:2798-2804.
24. Millan J., Pinto X., Munoz A., Zuniga M., Rubies-Prat J., Pallardo L.F., Masana L., Mangas A., Hernandez-Mijares A., Gonzalez-Santos P., Ascaso J.F., Pedro-Botet J. Lipoprotein ratios: physiological significance and clinical usefulness in cardiovascular prevention. Vasc. Health Risk Manag. 2009, 5:757-765.
25. Oh S.S., Hayes J.M., Sims-Robinson C., Sullivan K.A., Feldman E.L. The effects of anesthesia on measures of nerve conduction velocity in male C57Bl6/J mice. Neurosci. Lett. 2010, 483:127-131.
26. Poirier J. Apolipoprotein E and Alzheimer's disease. A role in amyloid catabolism. Ann. N. Y. Acad. Sci. 2000, 924:81-90.
27. Singleton J.R., Smith A.G., Bromberg M.B. Painful sensory polyneuropathy associated with impaired glucose tolerance. Muscle Nerve 2001, 24:1225-1228.
28. Smith A.G., Russell J., Feldman E.L., Goldstein J., Peltier A., Smith S., Hamwi J., Pollari D., Bixby B., Howard J., Singleton J.R. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006, 29:1294-1299.
29. Sullivan K.A., Hayes J.M., Wiggin T.D., Backus C., Su Oh S., Lentz S.I., Brosius F., Feldman E.L. Mouse models of diabetic neuropathy. Neurobiol. Dis. 2007, 28:276-285.
30. Sullivan K.A., Lentz S.I., Roberts J.L., Feldman E.L. Criteria for creating and assessing mouse models of diabetic neuropathy. Curr. Drug Targets 2008, 9:3-13.
31. Trauner M., Claudel T., Fickert P., Moustafa T., Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig. Dis. 2010, 28:220-224.
32. Vincent A.M., Hayes J.M., McLean L.L., Vivekanandan-Giri A., Pennathur S., Feldman E.L. Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1. Diabetes 2009, 58:2376-2385.
33. Vincent A.M., Hinder L.M., Pop-Busui R., Feldman E.L. Hyperlipidemia: a new therapeutic target for diabetic neuropathy. J. Peripher. Nerv. Syst. 2009, 14:257-267.
34. Wiggin T.D., Sullivan K.A., Pop-Busui R., Amato A., Sima A.A., Feldman E.L. Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 2009, 58:1634-1640.
35. Zhang H., Wu L.M., Wu J. Cross-talk between apolipoprotein E and cytokines. Mediators Inflamm. 2011, 2011:949072.